Press release
The UPS301 is a new model developed by Shenzhen Richroc Company.
This compact unit has three output ports. From left to right, people'll find two 12V DC input ports with a maximum of 2A, and a 9V 1A output, making it ideal for powering 12V and 9V ONUs or routers.The total output power is 27 watts, which means that the combined power of all connected devices should not exceed this limit.Its standard accessories include two DC cables, and the UPS301 is commonly used in applications involving one 12V ONU and either a 9V or 12V router. It offers a capacity of either 7800mAh or 6000mAh, composed of three 18650 lithium-ion cells (2000mAh or 2600mAh) connected in series.With a capacity of 7800mAh, this model can provide a backup time of 5 hours for 6W devices.
Image: https://www.wgpups.com/uploads/UPS301%E8%AF%A6%E6%83%85%E9%A1%B5-%E8%8B%B1%E6%96%87%E6%94%B9_05.jpg
Image: https://www.abnewswire.com/uploads/865342647bba18ebb5cab1789fe84d11.jpg
This model is also a plug-and-play device and is very simple to operate. How do people charge this model? It is designed to share their 12V device's plug. Simply connect the mini UPS to the city power using their 12V device's plug, and then use the provided cable to connect their devices. Ensure that the UPS is always turned on, and in the event of a power failure, our mini UPS will immediately provide power to their devices. The UPS connection is illustrated in the pictures below. As people can see, the setup is easy to understand for customers.
This is a new model on the market, and if people are looking to offer their customers more UPS options, it's definitely worth considering. For more information, feel free to send us an enquiry.
Media Contact
Company Name: Shenzhen Richroc Electronic Co., Ltd.
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=the-ups301-is-a-new-model-developed-by-shenzhen-richroc-company]
Country: China
Website: https://www.wgpups.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release The UPS301 is a new model developed by Shenzhen Richroc Company. here
News-ID: 3800405 • Views: …
More Releases from ABNewswire
Philip DeBerard Family Foundation Wins Judges Choice Award at 2025 Stuart Christ …
The Philip DeBerard Family Foundation, a community-focused nonprofit based in Stuart, Florida, captured statewide attention this holiday season after winning Judges Choice and the Large Float Classic Christmas Award at the Visiting Nurse Association of Florida Stuart Christmas Parade with its unforgettable and crowd-pleasing float titled "Grandma Got Run Over By a Brightline."
Presented during the annual Visiting Nurse Association of Florida 2025 Stuart Christmas Parade, the float featured a humorous,…
Growth Hormone Deficiency Market Insights Highlight Expanding Outlook Till 2034, …
The Key Growth Hormone Deficiency Companies in the market include - Novo Nordisk, Ascendis Pharma, Double Point Ventures (Lumos Pharma), SCOHIA PHARMA, and others.
The Growth Hormone Deficiency market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage pipeline products will significantly revolutionize the Growth Hormone Deficiency market dynamics.
DelveInsight's "Growth Hormone Deficiency Market Insights, Epidemiology, and Market Forecast-2034 report offers…
FDCTech, Inc. (OTC: FDCT) Poised to Capitalize on the Retail Trading Boom
Retail trading has emerged as a powerful force in global markets, with participation rising from roughly 25% of all trading activity in 2020 to over 30% by 2024. This surge has driven growing demand for social investing tools, copy trading features, and automated strategies, with analysts projecting these platforms could generate several billion dollars in annual revenue by the end of the decade.
At the same time, evolving regulatory frameworks, such…
Actinium Pharmaceuticals (NYSEAMERICAN: ATNM) Begins European Phase 1 Trial of N …
Innovation in oncology continues to accelerate, with global cancer R&D spending now exceeding hundreds of billions annually and more than a thousand new trials launched each year. Among the fastest-growing segments is radiopharmaceuticals, attracting significant investment as major pharmaceutical companies expand into precision radiation therapies. Growth has been fueled by strong clinical performance, improving isotope supply chains, and a wave of multibillion-dollar acquisitions that underscore investor confidence in targeted radiotherapy…
